The role of 5-alpha-reductase inhibitors in active surveillance

David Margel*, Neil Fleshner

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

PURPOSE OF REVIEW: Active surveillance is now considered one of the preferred treatments for men with favorable risk prostate cancer (PCa). Unfortunately, 30-50% of men choosing active surveillance will progress and require therapy. In this context, we will present recent data on the efficacy of 5-alpha-reductase inhibitors (5-ARIs) in secondary prevention among men with low-risk PCa choosing active surveillance. RECENT FINDINGS: Two recent studies including a multicenter randomized controlled study demonstrate that 5-ARI may reduce the rate of clinical progression in low-risk PCa. SUMMARY: 5-ARIs may play an important role in secondary prevention in low-risk PCa. These results should be interpreted with caution in view of the recent US Food and Drug Administration recommendation against PCa chemoprevention labeling for 5-ARIs.

Original languageEnglish
Pages (from-to)243-246
Number of pages4
JournalCurrent Opinion in Urology
Volume22
Issue number3
DOIs
StatePublished - May 2012
Externally publishedYes

Keywords

  • 5-alpha-reductase inhibitors
  • active surveillance
  • chemoprevention
  • low-risk prostate cancer

Fingerprint

Dive into the research topics of 'The role of 5-alpha-reductase inhibitors in active surveillance'. Together they form a unique fingerprint.

Cite this